Good publication practice for pharmaceutical companies
Good publication practice for pharmaceutical companies
复制标题
DOI：
10.1185/030079903125001767
复制
发表时间：
2003-01-01
影响因子：
2.3
通讯作者：
Grossman, L
中科院分区：
文献类型：
--
作者：
Wager, E;Field, EA;Grossman, L
提出了制药公司的良好出版实践 (GPP) 指南。该指南的目的是确保制药公司赞助的临床试验以负责任和道德的方式发布。该指南涵盖了公司努力公布所有研究结果的责任、公司与研究者的关系、防止重复或过早发表的措施、改进试验识别的方法以及专业医学撰稿人的作用。我们发布 GPP 指南的目的是激发期刊、研究人员和试验申办者之间的讨论，并为寻求指南的人提供指导，该指南是第一个由制药行业出版物工作人员制定的指南。我们还希望制药公司和其他参与开发赞助临床试验出版物的机构能够认可该指南。
Guidelines on Good Publication Practice (GPP) for pharmaceutical companies are presented. The aim of the guidelines is to ensure that clinical trials sponsored by pharmaceutical companies are published in a responsible and ethical manner. The guidelines cover companies' responsibility to endeavour to publish results of all studies, companies' relations with investigators, measures to prevent redundant or premature publication, methods to improve trial identification and the role of professional medical writers. Our aim in publishing the GPP guidelines, which are the first to be developed by and for those working on publications in the pharmaceutical industry, is to stimulate discussion between journals, investigators and trial sponsors and to provide guidance to those who seek it. We also hope that pharmaceutical companies and others involved in developing publications arising from sponsored clinical trials will endorse the guidelines.